NASDAQ : GOVX
GeoVax Labs, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.1859 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.69M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.53M |
| Enterprise Value | -1.29M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 9.09M |
| Shares Outstanding | 9.09M |
| Shares Change (YoY) | +439.21% |
| Shares Change (QoQ) | +127.34% |
| Owned by Insiders (%) | 6.06% |
| Owned by Institutions (%) | 9.18% |
| Float | 8.54M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.71 |
| P/TBV Ratio | 0.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.54 |
| Quick Ratio | 1.16 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -891.59% |
| Return on Assets (ROA) | -256.80% |
| Return on Invested Capital (ROIC) | -523.18% |
| Return on Capital Employed (ROCE) | -1,063.58% |
| Weighted Average Cost of Capital (WACC) | 20.25% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.08M |
| Employee Count | 19 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 3.69 |
| 52-Week Price Change | -98.78% |
| 50-Day Moving Average | 0.38 |
| 200-Day Moving Average | 1.26 |
| Relative Strength Index (RSI) | 17.16 |
| Average Volume (20 Days) | 916,401 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 270,211 |
| Short Previous Month | 281,773 |
| Short % of Shares Out | 2.97% |
| Short % of Float | 3.16% |
| Short Ratio (days to cover) | 0.32 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -15.05M |
| Operating Income | -20.53M |
| Pretax Income | -20.43M |
| Net Income | -20.43M |
| EBITDA | -20.47M |
| EBIT | -20.53M |
| Earnings Per Share (EPS) | -$8.75 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.14M |
| Total Debt | 323,141 |
| Net Cash | 2.82M |
| Net Cash Per Share | $0.31 |
| Equity (Book Value) | 1.76M |
| Book Value Per Share | 0.24 |
| Working Capital | 1.46M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -18.37M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 59,184 |
| Net Borrowing | n/a |
| Free Cash Flow | -18.37M |
| FCF Per Share | -$2.02 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -439.21% |
| Shareholder Yield | -439.21% |
| Earnings Yield | -5,192.06% |
| FCF Yield | -1,198.11% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $10.00 |
| Price Target Difference | 5,831.20% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 12, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -60.48 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |